BGMD:OTC-BG Medicine, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC

Last Closing Price

USD 0.03

Change

+0.00 (+17.58)%

Market Cap

USD 0.46M

Volume

625.00

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-28 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ESLOF EssilorLuxottica Société ano..

N/A

USD80.38B 814.11 32.43
ESLOY EssilorLuxottica Société ano..

N/A

USD79.84B 809.02 32.43
HOCPF HOYA Corporation

N/A

USD50.08B 45.16 0.24
HOCPY HOYA Corporation

N/A

USD49.64B 44.77 0.24
SDMHF Sartorius Stedim Biotech S.A

N/A

USD49.54B 88.23 61.12
RSMDF ResMed Inc

N/A

USD42.79B 33.65 35.74
CLPBY Coloplast A/S

N/A

USD38.06B 56.01 5.91
CLPBF Coloplast A/S

N/A

USD37.71B 53.95 5.91
TRUMF Terumo Corporation

+0.90 (+2.31%)

USD29.29B 41.93 0.19
TRUMY Terumo Corporation

N/A

USD29.02B 41.54 0.19

ETFs Containing BGMD

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -57.00% 7% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.00% 7% F 5% F
Trailing 12 Months  
Capital Gain 49.01% 60% D- 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.01% 57% F 58% F
Trailing 5 Years  
Capital Gain -84.95% 10% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -84.95% 10% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain 19.95% 32% F 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.95% 27% F 56% F
Risk Return Profile  
Volatility (Standard Deviation) 114.57% 35% F 31% F
Risk Adjusted Return 17.42% 20% F 37% F
Market Capitalization 0.46M 14% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -0.13 79% C+ 58% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -902.64% 2% F 2% F
Return on Invested Capital -580.53% 3% F 2% F
Return on Assets -75.95% 14% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.66 25% F 25% F
Short Percent 7.58% 25% F 18% F
Beta 0.83 31% F 52% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.